TY - JOUR
T1 - Rational treatment of pulmonary infections in patients with cystic fibrosis
AU - Foca, Marc
AU - Rajan, Sujatha
AU - Saiman, Lisa
PY - 1999
Y1 - 1999
N2 - The life expectancy of patients with cystic fibrosis has increased markedly during the past two decades due in large part to improved clinical care, including the use of more effective antimicrobial agents for Pseudomonas. However, the chronic lung disease of CF remains the principal cause of mortality. A growing understanding of the complex interactions between infection and inflammation has led to new approaches for treatment, including chronic use of aerosolized antibiotics, particularly tobramycin, in patients known to be colonized/infected with P. aeruginosa and anti-inflammatory treatments to slow the progression of lung disease.
AB - The life expectancy of patients with cystic fibrosis has increased markedly during the past two decades due in large part to improved clinical care, including the use of more effective antimicrobial agents for Pseudomonas. However, the chronic lung disease of CF remains the principal cause of mortality. A growing understanding of the complex interactions between infection and inflammation has led to new approaches for treatment, including chronic use of aerosolized antibiotics, particularly tobramycin, in patients known to be colonized/infected with P. aeruginosa and anti-inflammatory treatments to slow the progression of lung disease.
UR - http://www.scopus.com/inward/record.url?scp=0032856237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032856237&partnerID=8YFLogxK
U2 - 10.1097/00001432-199906000-00017
DO - 10.1097/00001432-199906000-00017
M3 - Review article
C2 - 17035789
AN - SCOPUS:0032856237
SN - 0951-7375
VL - 12
SP - 257
EP - 263
JO - Current Opinion in Infectious Diseases
JF - Current Opinion in Infectious Diseases
IS - 3
ER -